aliskirendirect renin inhibitorsarterial hypertensionnephroprotectionалискиренпрямые ингибиторы ренинаартериальная гипертензиянефропротекция1.1. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестн. РАМН. 2003; 11: 50-5.2.2. De Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004; 66: 2109-18.3.3. ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.4.4. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). М., 2008.5.5. The ESH - ESC Task Force. 2007 Guidelines for the Management of the Arterial Hypertension. J Hypertens 2007; 25: 1105-87.6.6. Schmieder RE, Schrader J, Zidek W et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007; 96 (5): 247-57.7.7. Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112 (7): 969-75.8.8. Lieb W, Mayer B, Stritzke J et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol. Dial. Transplant. 2006; 21 (10): 2780-7.9.9. Sung KC, Kim BJ, Ryu S. An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. Atherosclerosis 2008; 196 (1): 320-6.10.10. Wang TJ, Evans JC, Meigs JB et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111 (11): 1370-6.11.11. Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc Pharmacol2006; 47 (Suppl. 2): S151-62.12.12. Tsakiris A, Doumas M, Lagatouras D et al. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology 2006; 57 (3): 313-20.13.13. Metclaf P, Baker J, Scott A et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension and hyperlipidemia. Clin Chem 1992; 38: 1802-8.14.14. Redon J, Miralles A, Pascual JM et al. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15 (1): 79-86.15.15. Shankar SS, Steinberg HO. Obesity and endothelial dysfunction. Semin Vasc Med 2005; 5: 56-64.16.16. Lekatsas I, Koulouris S, Triantafyllou K et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction. Int J Cardiol 2006; 106 (2): 218-23.17.17. Szczudlik A, Turaj W, Slowik A, Strojny J. Microalbuminuria and hyperthermia independently predict long-term mortality in acute ischemic stroke patients. Acta Neurol Scand 2003; 107: 96-101.18.18. Terao Y, Miura K, Ichinomiya T et al. Admission microalbuminuria and neurologic outcomes in intensive care unit patients with spontaneous intracerebral hemorrhage. J Neurosurg Anesthesiol 2008; 20 (3): 163-8.19.19. Barzilay JI, Fitzpatrick AL, Luchsinger J et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis 2008; 52 (2): 216-26.20.20. Wachtell K, Palmieri V, Olsen MH et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143 (2): 319-26.21.21. Torun D, Sezer S, Arat Z et al. The frequency of combined target organ damage and the beneficial effect of ambulatory blood pressure monitoring in never treated mild-to-moderate hypertensive patients. Int Heart J 2005; 46 (6): 1073-82.22.22. Munakata M, Nunokawa T, Yoshinaga K et al. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension - a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res 2006; 29 (7): 515-21.23.23. Dalla Vestra M, Mussap M, Gallina P et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16 (Suppl. 1): S78-82.24.24. Fаrbom P, Wahlstrand B, Almgren P et al. Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the Nordic diltiazem study. Hypertension 2008; 52 (1): 115-22.25.25. Furtner M, Kiechl S, Mair A et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J 2005; 26: 279-87.26.26. Baber U, Mann D, Shimbo D et al. Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol 2009; 104 (10): 1446-51.27.27. Escobedo J, Rana JS, Lombardero MS et al. BARI 2D Study Group. Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study. Mayo Clin Proc 2010; 85 (1): 41-6.28.28. Bоhm M, Reil JC, Danchin N et al. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 2008; 26 (1): 18-25.29.29. Boersma C, Postma MJ, Visser ST et al. PREVEND Study Group. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Br J Clin Pharmacol 2008; 65 (5): 723-32.30.30. Eguchi K, Matsui Y, Shibasaki S et al. Changes in self-monitored pulse pressure correlate with improvements in B-type natriuretic peptide and urinary albumin in treated hypertensive patients. Am J Hypertens 2007; 20 (12): 1268-75.31.31. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol 2008; 21 (4): 566-9.32.32. Cottone S, Mule G, Nardi E et al. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens 2006; 36: 115-8.33.33. Jordan J, Engeli S, Boye SW et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-55.34.34. Dahlоf B, Anderson DR, Arora V et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension (abstr). J Clin Hypertens 2007; 9 (Suppl. A): A157.35.35. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15 (2): 276-82.36.36. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 2007; 370: 221-9.37.37. Parving HH, Persson F, Lewis JB et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358 (23): 2433-46.38.38. Persson F et al. Renoprotective effects of direct renin inhibition compared to and in combination with maximum recommended dose of Irbesartan in patients with type 2 diabetes and albuminuria. Diabetologia 2008; 51 (Suppl. 1): S492.39.39. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24 (5): 1663-71.